

Anti-virulence therapeutic strategies against bacterial infections: recent advances

Razieh Dehbanipour¹, Zohreh Ghalavand^{2,*}

Abstract

The emergence and increasing prevalence of multidrug-resistant pathogens has become a major global healthcare problem. According to the World Health Organization if these trends continue, mortality from infection in 2050 will be higher than that from cancer. Microorganisms have various resistance mechanisms against different classes of antibiotics that emphasize the need for discovery of new antimicrobial compounds to treat bacterial infections. An interesting and new strategy for disarming pathogens is antivirulence therapy by blocking bacterial virulence factors or pathogenicity. Therefore, the use of these new pathoblockers could reduce the administration of broad-spectrum antimicrobials and prevalence of resistant strains.

This review provides an overview of the antivirulence strategies published studies between years 2017 and 2021. Most antivirulence strategies focused on adhesins, toxins and bacterial communication. Additionally, targeting two-component systems and ncRNA elements were also examined in some studies. These new strategies have the potential to replace traditional antimicrobial agents and can be used to treat infections, especially infections caused by resistant pathogens, by targeting virulence factors.

Keywords Antivirulence therapeutics, pathoblockers, antimicrobial resistance, virulence factors, antiadherence strategies, antibiofilm activity, quorum sensing, secretion systems, two-component systems, non-coding RNA.

Introduction

Antimicrobial resistance is a significant global public health threat. The emergence of multidrug resistance in ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species), responsible for serious chronic nosocomial

infections, has become a serious challenge worldwide.¹ On the other hand, new classes of resistance mechanisms such as metabolic gene alterations may be a new concern to human health.² Resistance expansion prevents efficient treatment of infected patients, especially in the hospital setting. All of these threats emphasize the need to identify new strategies for the treatment of bacterial infectious diseases. In this review we highlight antivirulence approaches that are being investigated for the prevention and treatment of bacterial infections. It should be noted that, among the compounds identified and studied for antivirulence therapy, a few have been tested using *in vivo* models.

Review criteria

This review provides an overview of the antivirulence strategies research. Published works on antivirulence therapy studies from years 2017 to 2021 were identified using the following search terms “antivirulence therapeutics”, “pathoblockers”, “new therapeutic strategies” in Google Scholar, PubMed, Medline and Scopus. The final sample consisted of 77 articles after

Received: 12 August 2021; revised: 30 January 2022 and 03 April 2022; accepted: 05 April 2022.

¹PhD, Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Koodakyar St, Tabnak Blv., Yaman Av., Chamran Highway, Tehran, Iran; ²PhD, Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Koodakyar St, Tabnak Blv., Yaman Av., Chamran Highway, Tehran, Iran.

*Corresponding author: Zohreh Ghalavand, zghalavand@sbmu.ac.ir

Article downloaded from www.germs.ro

Published June 2022

© GERMS 2022

ISSN 2248 - 2997

ISSN - L = 2248 - 2997

processing and applying exclusion criteria, and are presented as follows.

Antivirulence strategies

Virulence is a microorganism's ability to produce disease. Virulence factors are molecules produced by a variety of microbial pathogens that assist in colonization, immuno-evasion, immunosuppression, obtaining nutrition and damaging host cells. These factors are often classified in three forms, including membrane associated, secretory or cytosolic.³ Blocking the activities of virulence factors is a new approach that has emerged over the last decade. Antivirulence drugs, the new class of drugs, target virulence factors of pathogens instead of killing or stopping their growth and consequently disarm infectious pathogens. Bactericidal antibiotics may also cause the selective pressure that drives resistance. Antivirulence drugs interfere with the interaction of the pathogen with its host, and thereby reduce damage to the host and impair the organism's ability to cause disease without killing it or creating selective pressure.⁴ Research on the inactivation of diphtheria and tetanus toxins are the first examples of the antivirulence approach.^{5,6} Also, bezlotoxumab is the first antivirulence agent approved by the US food and drug administration (FDA). This agent blocks TcdB in *Clostridioides difficile*.⁷ There are a variety of bacterial targets for antivirulence therapy, however some of the most attractive targets are adhesins, toxins, bacterial communication, two component systems and non-coding RNAs. Studies in recent years have suggested a variety of compounds as candidates for antivirulence therapies (Table 1).

Antiadherence strategies

Adhesion to host tissues is the initial step of infectious diseases caused by pathogenic bacteria. Therefore, inhibiting bacterial adherence by antivirulence drugs can be a promising strategy to prevent infection.

Gram-positive pathogens including staphylococci, enterococci and streptococci can express various surface adhesion proteins known as MSCRAMM (microbial surface component

recognizing adhesive matrix molecules). In addition to bacterial adhesion, MSCRAMM play important roles in immune evasion and biofilm formation. On the other hand, sortaseA (SrtA), a membrane-localized cysteine transpeptidase in Gram-positive pathogens, is crucial for the assembly and anchoring of aforementioned cell-surface adhesins to the cell wall envelope. Due to its easy accessibility and lack of homologous sortase in eukaryotes, it is a promising drug target for the development of antivirulence therapeutics against Gram-positive bacterial infections. Additionally, if the selective pressure induced by inhibitors results in mutation in the SrtA gene or an increase in enzyme production to counteract the decrease in enzymatic activity, it finally leads to a reduction in pathogenicity of the pathogen through decreasing enzyme activity and increasing metabolic burden, respectively. To date, various natural products and synthetic small molecules have been discovered as SrtA inhibitory compounds.^{8,9}

Moreover, one of the most significant strategies for bacteria to counteract antimicrobials is biofilm formation. Bacterial cells are embedded in a self-produced extracellular matrix within biofilms. The antimicrobial resistance of biofilm cells is up to a thousand times higher than that of planktonic forms, and it may be linked to accumulation of resistance mechanisms of single cells within biofilms. Biofilms are involved in chronic and recurrent infections caused by pathogens such as *P. aeruginosa*, *A. baumannii*, *S. aureus*, *E. coli*, *K. pneumoniae* and *Streptococcus pneumoniae* (Figure 1). Furthermore, the presence of bacterial cells in the depth of metabolically inactive cell layers makes it difficult for antibiotics to access them and penetrate the matrix. Given the importance of biofilm in bacterial pathogenicity, it seems to be an attractive target for anti-virulence drug development. The main approach in this regard is based on two strategies: 1) inhibition of biofilm formation by preventing bacterial cells from adhesion to the host tissue and 2) disruption of biofilm communities. To date, various inhibitory compounds have been identified and introduced to achieve these goals.¹⁰ For example, a large number of synthetic small molecules have been



Figure 1. Biofilm-associated infections

identified in recent years that have an interesting capability to target the biofilm formation at different stages.¹¹

Targeting toxins and secretion systems

The type III secretion system (T3SS) is one of the most important virulence factors used by some Gram-negative pathogens such as *P. aeruginosa*, *Salmonella enterica* serovar Typhimurium, *Yersinia pestis* and *Chlamydia* spp. *P. aeruginosa* is capable to infect a wide host range and lead to high mortality rates, especially in patients with cystic fibrosis (CF). This pathogen utilizes the type III secretion system to transport bacterial effectors, ExoS, ExoU, ExoT and ExoY, directly into host cells. T3SS consists of a series of regulated genes that encode components of the secretion apparatus and a translocon, and are important for intoxication of eukaryotic cells.¹² Since the T3SS machinery is evolutionarily conserved, it can be used as a potential target for pathoblockers. In addition, because T3SS is required for pathogenesis but not for survival, the use of inhibitors results in attenuated virulence as well as less selective pressure for resistance. INP0341, a salicylidene acylhydrazide, is a promising substance that has been shown to inhibit T3SS in a range of Gram-negative

bacteria, resulting in preventing toxin delivery and, hence, decreasing bacterial virulence.¹³

Aggregatibacter actinomycetemcomitans is a member of the HACEK group of bacteria together with *Haemophilus* spp., *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella kingae*. Although these fastidious Gram-negative organisms are found in the human oral cavity and known as the normal flora, they can cause various invasive infections, particularly endocarditis and localized aggressive periodontitis (LAP). *A. actinomycetemcomitans* colonizes the gingival sulcus and invades the epithelial tissues and stimulates a pathophysiologic inflammatory response.¹⁴ This organism has different virulence factors including adhesive type IV pili, surface-exposed autotransporter proteins, type V collagen, leukotoxin and lipopolysaccharide. The operon of leukotoxin is comprised of four coding genes including *ltxC*, *ltxA*, *ltxB*, and *ltxD*. *LtxA* is a large pore-forming toxin and a key virulence factor, which has the ability to annihilate host immune tissues.¹⁵ Since *LtxA* has strong affinity for plasma membrane cholesterol-rich lipid rafts, inhibitors such as catechins can prohibit *LtxA*-mediated cytotoxicity in white blood cells through altering *LtxA* structure and reducing affinity for cholesterol. Catechin is one group of

flavonoids derived from plants, with a variety of health beneficial effects through antioxidant, anticancer, antimicrobial and antiviral properties. Therefore, catechin and its derivatives are potential compounds to be used as antivirulence agents.¹⁶ In addition, MEDI4893 (suvratomumab) and AR-301 are two monoclonal neutralizing antibodies against α -hemolysin (Hla) in *S. aureus*.^{17,18} MEDI4893 has completed phase 2 clinical trials and AR-301 had entered phase 3 trials for the prevention of *S. aureus* pneumonia.¹⁹

Targeting quorum sensing

Bacterial quorum sensing (QS) is a comprehensive phenomenon that involves the ability to react to cell-population density via gene regulation. QS involves extracellular signaling molecules, also called autoinducers (AIs). This chemical communication is a critical pathway for survival in a competitive environment, for nutrient uptake and cell growth.²⁰ Gram-positive bacteria use a two-component system that is comprised of membrane-bound sensor kinase receptors and cytoplasmic transcription factors phosphorylated by kinase which then regulate gene expression. Gram-negative bacteria, including *Pseudomonas* spp., *Acinetobacter* spp., or *Burkholderia* spp. employ another type of autoinducers, the acyl-homoserine lactones (AHLs) which, after binding to a regulatory protein in the cell, operate as a transcription factor for various enzymes and virulence factor secretion genes.²¹ Many virulence traits are influenced by QS and thus targeting QS can be a hopeful strategy to inhibit bacterial infections and combat the growing problem of antibiotic resistance. Interference with QS, called quorum quenching (QQ), is a process of obstructing QS by impeding signaling. This process consists of several parts, including inhibition of signaling molecules, blocking the receptor of signaling molecules by mimic molecules, degradation of signaling molecules and amendment of the QS signals by the enzyme activity. The use of nanotechnology in combination with antivirulence therapy in the treatment of diseases seems to be a promising strategy to confront pathogens. Selenium nanoparticles (SeNPs) as a

drug carrier have shown significant effects on the intracellular delivery of antivirulence compounds such as polyphenols of honey with anti-QS activity against *P. aeruginosa*.²²

Four essential oils (clove, cinnamon, thyme and marjoram) have been reported to have anti-biofilm and anti-QS activities against Gram-negative and Gram-positive multidrug-resistant pathogens such as *E. coli*, *P. aeruginosa*, *K. pneumoniae*, *A. baumannii* and *S. aureus*.²³

Targeting two-component systems

Two-component systems (TCSs) are involved in sensing environmental changes and expression of genes responding to environmental signals. They consist of a membrane-bound histidine kinase and a corresponding cytoplasmic response regulator that accomplish signal transduction by phosphorylation. TCSs play important roles in bacterial functions including drug resistance and host invasion. Studies characterized some TCSs that control gene networks in reaction to osmolarity, secondary metabolites, temperature, nutrients and ions. These include: DosR/DosS, EnvZ/OmpR, RcsB/RcsC, PhoP/PhoQ, BarA/SirA, CpxR/CpxS, AgrC/AgrA, and QseC/QseB.^{24,25}

The DosRST two-component regulatory system has an important role in virulence in *Mycobacterium tuberculosis* (Mtb). Studies on two chemical inhibitors including HC104A and HC106A demonstrated that the compounds downregulate the DosR regulon genes and disrupt signal transduction leading to decreased Mtb survival.²⁶ Savirin, a small molecule inhibitor, reduces the expression of AgrCA-regulated genes and also inhibits RNAPIII production in *S. aureus*, thus leading to a reduction of virulence. However, savarin has no effect on skin commensal *Staphylococcus epidermidis*.²⁷

Non-coding RNAs as novel antimicrobial targets

A non-coding RNA (ncRNA), is a functional RNA molecule that operates without the need for being translated. In general, ncRNAs are involved in biofilm formation, regulation of gene

expression responding to extracellular stress and preserving homeostasis of the microbial cell at the transcriptional and post-transcriptional level. Some small non-coding RNAs (sRNAs) function to regulate genes that confer antibiotic resistance. CsiR in *Proteus vulgaris* were found to regulate EmrB multidrug efflux pump and are involved in the regulation of ciprofloxacin resistance.²⁸ On the other hand, since sRNAs are expressed in different growth phases of the bacterial life, it is suggested that the presence of sRNAs in the disease progression process is necessary to reconcile with the environmental changes.²⁹

Since ncRNA can control biofilm formation, antibiotic resistance and bacterial stress responses, targeting the ncRNA pathways is a promising strategy for overcoming bacterial infections.

Discussion

The use of antibiotics has greatly helped in the treatment and control of infections during the 20th century but the widespread usage of conventional antibiotics has led to alarming increases in antibiotic resistance, even last-resort antibiotics like colistin, and failure to treat persistent infections. In recent years, an approach based on antivirulence therapeutics has become a promising strategy to counteract human pathogens. Interestingly, synergy between different antivirulence compounds with distinct targets is an attractive approach to use combination therapy to enhance the anti-pathogenic effect.³⁰

However, one of the limitations of antivirulence therapies is the inability to completely clear the infection, which is challenging in clinical applications especially for immunocompromised patients. It seems that antivirulence compounds in combination with antibiotics can overcome this limitation. In fact, the use of antivirulence compound makes it possible to use lower concentrations of antibiotics, minimizing side effects and reducing the generation of antibiotic resistance in pathogens as well as effective pathogen removal. A study on the combination of gallium and furanone (as antivirulence compounds) together

with antibiotics (colistin, ciprofloxacin, tobramycin and meropenem) in *P. aeruginosa* showed a significant effect of combination therapy in limiting the spread of antibiotic resistance. Interestingly, it has been suggested that the effectiveness of combination therapy is linked to the molecular mechanism of antibiotic resistance.³¹ However, proving this hypothesis requires more detailed and comprehensive studies. Although these studies promise new therapeutic approaches, more research is needed for clinical applications. Since drug interactions are concentration dependent, pharmacodynamics and pharmacokinetics studies are required. In addition, there is evidence that antivirulence compounds may, contrary to expectations, in certain instances act in vivo as signals for activation of virulence factors in pathogens.³² Hence, animal models must be used to evaluate the effectiveness of antivirulence compounds, alone or in combination with antibiotics, in the host environment.

Conclusions

Here, we reviewed current antivirulence strategies to disarm pathogens by targeting bacterial virulence factors. It should be noted that this strategy, like the use of antibiotics, also has disadvantages including lack of effect on all forms of the disease and low therapeutic effects compared with antibiotics. Because many of the pathogenicity mechanisms in pathogens are unknown, extensive studies on the virulence factors of pathogens and host-pathogen interactions are needed to advance this strategy. Appropriate and ongoing cooperation between governments and pharmaceutical companies can create a great future for new treatment strategies.

Authors' contributions statement: RD conceptualized, designed, searched for the review articles, read through, analyzed, interpreted them and wrote the first draft of the manuscript. ZG read the draft manuscript and revised it for important intellectual content. All authors read and approved the final manuscript.

Conflicts of interest: All authors – none to declare.

Funding: This research did not receive funding from an external source, it was self-financed by the authors.

Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate: Not applicable.

References

- Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. *BioMed Res Int*. 2016;2016:2475067. <https://doi.org/10.1155/2016/2475067>
- Lopatkin AJ, Bening SC, Manson AL, et al. Clinically relevant mutations in core metabolic genes confer antibiotic resistance. *Science*. 2021;371:eaba0862. <https://doi.org/10.1126/science.aba0862>
- Sharma AK, Dhasmana N, Dubey N, et al. Bacterial virulence factors: secreted for survival. *Indian J Microbiol*. 2017;57:1-10. <https://doi.org/10.1007/s12088-016-0625-1>
- Calvert MB, Jumde VR, Titz A. Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections. *Beilstein J Org Chem*. 2018;14:2607-17. <https://doi.org/10.3762/bjoc.14.239>
- Schmitt CK, Meysick KC, O'Brien AD. Bacterial toxins: friends or foes? *Emerg Infect Dis*. 1999;5:224-34. <https://doi.org/10.3201/eid0502.990206>
- Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. *Clin Microbiol Rev*. 2000;13:602-14. <https://doi.org/10.1128/CMR.13.4.602>
- Dickey SW, Cheung GY, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. *Nat Rev Drug Discov*. 2017;16:457-71. <https://doi.org/10.1038/nrd.2017.23>
- Cascioferro S, Totsika M, Schillaci D, Sortase A: an ideal target for anti-virulence drug development. *Microb Pathog*. 2014;77:105-12. <https://doi.org/10.1016/j.micpath.2014.10.007>
- Zrelavs N, Kurbatska V, Rudevica Z, Leonchiks A, Fridmanis D. Sorting out the superbugs: potential of sortase A inhibitors among other antimicrobial strategies to tackle the problem of antibiotic resistance. *Antibiotics (Basel)*. 2021;10:164. <https://doi.org/10.3390/antibiotics10020164>
- Uruén C, Chopo-Escuin G, Tommassen J, Mainar-Jaime RC, Arenas J. Biofilms as promoters of bacterial antibiotic resistance and tolerance. *Antibiotics (Basel)*. 2020;10:3. <https://doi.org/10.3390/antibiotics10010003>
- Parrino B, Schillaci D, Carnevale I, et al. Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance. *Eur J Med Chem*. 2019;161:154-178. <https://doi.org/10.1016/j.ejmech.2018.10.036>
- Horna G, Ruiz J. Type 3 secretion system of *Pseudomonas aeruginosa*. *Microbiol Res*. 2021;246:126719. <https://doi.org/10.1016/j.micres.2021.126719>
- Sharma P, Eloffson M, Roy S. Attenuation of *Pseudomonas aeruginosa* infection by INP0341, a salicylidene acylhydrazide, in a murine model of keratitis. *Virulence*. 2020;11:795-804. <https://doi.org/10.1080/21505594.2020.1776979>
- Sharara SL, Tayyar R, Kanafani ZA, Kanj SS. HACEK endocarditis: a review. *Expert Rev Anti Infect Ther*. 2016;14:539-45. <https://doi.org/10.1080/14787210.2016.1184085>
- Gholizadeh P, Pormohammad A, Eslami H, Shokouhi B, Fakhrzadeh V, Kafil HS. Oral pathogenesis of *Aggregatibacter actinomycetemcomitans*. *Microb Pathog*. 2017;113:303-11. <https://doi.org/10.1016/j.micpath.2017.11.001>
- Wu M, Brown AC. Applications of catechins in the treatment of bacterial infections. *Pathogens*. 2021;10:546. <https://doi.org/10.3390/pathogens10050546>
- Yu XQ, Robbie GJ, Wu Y, et al. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-*Staphylococcus aureus* alpha-toxin human monoclonal antibody, in healthy adults. *Antimicrob Agents Chemother*. 2016;61:e01020-16. <https://doi.org/10.1128/AAC.01020-16>
- François B, Mercier E, Gonzalez C, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by *Staphylococcus aureus*: first-in-human trial. *Intensive Care Med*. 2018;44:1787-96. <https://doi.org/10.1007/s00134-018-5229-2>
- Ford CA, Hurford IM, Cassat JE. Antivirulence strategies for the treatment of *Staphylococcus aureus* infections: a mini review. *Front Microbiol*. 2021;11:632706. <https://doi.org/10.3389/fmicb.2020.632706>
- Papenfort K, Bassler BL. Quorum sensing signal-response systems in Gram-negative bacteria. *Nat Rev Microbiol*. 2016;14:576-88. <https://doi.org/10.1038/nrmicro.2016.89>
- Prabhu M, Naik M, Manerikar V. Quorum sensing-controlled gene expression systems in gram-positive and gram-negative bacteria. In: Bramhachari P (ed). *Implication of quorum sensing and biofilm formation in medicine, agriculture and food industry*. Singapore: Springer; 2019. pp. 11-20. https://doi.org/10.1007/978-981-32-9409-7_2
- Prateeksha, Singh BR, Shoeb M, Sharma S, Naqvi AH, Gupta VK, Singh BN. Scaffold of selenium nanovectors and honey phytochemicals for inhibition of *Pseudomonas aeruginosa* quorum sensing and biofilm formation. *Front Cell Infect Microbiol*. 2017;7:93. <https://doi.org/10.3389/fcimb.2017.00093>
- Alibi S, Ben Selma W, Ramos-Vivas J, et al. Anti-oxidant, antibacterial, anti-biofilm, and anti-quorum sensing activities of four essential oils against multidrug-resistant bacterial clinical isolates. *Curr Res Transl Med*. 2020;68:59-66. <https://doi.org/10.1016/j.retram.2020.01.001>
- Rajput A, Seif Y, Choudhary KS, et al. Pangenome analytics reveal two-component systems as conserved targets in ESKAPEE pathogens. *mSystems*.

- 2021;6:e00981-20.
<https://doi.org/10.1128/mSystems.00981-20>
25. Mühlen S, Dersch P. Anti-virulence strategies to target bacterial infections. In: Stadler M, Dersch P (eds). How to overcome the antibiotic crisis. Curr Top Microbiol Immunol. Cham: Springer. 2016;398:147-183.
https://doi.org/10.1007/82_2015_490
 26. Zheng H, Williams JT, Alewi B, Ellsworth E, Abramovitch RB. Inhibiting *Mycobacterium tuberculosis* DosRST signaling by targeting response regulator DNA binding and sensor kinase heme. ACS Chem Biol. 2020;15:52-62.
<https://doi.org/10.1021/acscchembio.8b00849>
 27. Salam AM, Quave CL. Targeting virulence in *Staphylococcus aureus* by chemical inhibition of the accessory gene regulator system in vivo. mSphere. 2018;3:e00500-17.
<https://doi.org/10.1128/mSphere.00500-17>
 28. Zhang H, Song T, Qin C, Xu H, Qiao M. A novel non-coding RNA CsiR regulates the ciprofloxacin resistance in *Proteus vulgaris* by interacting with emrB mRNA. Int J Mol Sci. 2021;22:10627.
<https://doi.org/10.3390/ijms221910627>
 29. Xia L, Xia W, Li S, et al. Identification and expression of small non-coding RNA, L10-Leader, in different growth phases of *Streptococcus mutans*. Nucleic Acid Ther. 2012;22:177-86.
<https://doi.org/10.1089/nat.2011.0339>
 30. Aburto-Rodríguez NA, Muñoz-Cázarez N, Castro-Torres VA, et al. Anti-pathogenic properties of the combination of a T3SS inhibitory halogenated pyrrolidone with C-30 furanone. Molecules. 2021;26:7635.
<https://doi.org/10.3390/molecules26247635>
 31. Rezzoagli C, Archetti M, Mignot I, Baumgartner M, Kümmerli R. Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in *Pseudomonas aeruginosa*. PLoS Biol. 2020;18:e3000805.
<https://doi.org/10.1371/journal.pbio.3000805>
 32. Juárez-Rodríguez MM, Cortes-López H, García-Contreras R, et al. Tetradecanoic acids with anti-virulence properties increase the pathogenicity of *Pseudomonas aeruginosa* in a murine cutaneous infection model. Front Cell Infect Microbiol. 2021;10:597517.
<https://doi.org/10.3389/fcimb.2020.597517>
 33. Ping O, Mao S, Xuewen H, et al. Scleroel protects *Staphylococcus aureus*-induced lung cell injury via inhibiting alpha-hemolysin expression. J Microbiol Biotechnol. 2017;27:19-25.
<https://doi.org/10.4014/jmb.1606.06039>
 34. Liu Y, Shi D, Guo Y, et al. Dracorhodin perochlorate attenuates *Staphylococcus aureus* USA300 virulence by decreasing α -toxin expression. World J Microbiol Biotechnol. 2017;33:17.
<https://doi.org/10.1007/s11274-016-2129-x>
 35. Zhang B, Teng Z, Li X, et al. Chalcone attenuates *Staphylococcus aureus* virulence by targeting sortase A and alpha-hemolysin. Front Microbiol. 2017;8:1715.
<https://doi.org/10.3389/fmicb.2017.01715>
 36. Teng Z, Shi D, Liu H, et al. Lysionotin attenuates *Staphylococcus aureus* pathogenicity by inhibiting α -toxin expression. Appl Microbiol Biotechnol. 2017;101:6697-703.
<https://doi.org/10.1007/s00253-017-8417-z>
 37. Edwards GA, Shymanska NV, Pierce JG. 5-Benzylidene-4-oxazolidinones potently inhibit biofilm formation in methicillin-resistant *Staphylococcus aureus*. Chem Commun (Camb). 2017;53:7353-6.
<https://doi.org/10.1039/C7CC03626D>
 38. Ming D, Wang D, Cao F, et al. Kaempferol inhibits the primary attachment phase of biofilm formation in *Staphylococcus aureus*. Front Microbiol. 2017;8:2263.
<https://doi.org/10.3389/fmicb.2017.02263>
 39. Garcia S, Blackledge M, Michalek S, et al. Targeting of *Streptococcus mutans* biofilms by a novel small molecule prevents dental caries and preserves the oral microbiome. J Dent Res. 2017;96:807-814.
<https://doi.org/10.1177/0022034517698096>
 40. Rajamanikandan S, Jeyakanthan J, Srinivasan P. Molecular docking, molecular dynamics simulations, computational screening to design quorum sensing inhibitors targeting LuxP of *Vibrio harveyi* and its biological evaluation. Appl Biochem Biotechnol. 2017;181:192-218.
<https://doi.org/10.1007/s12010-016-2207-4>
 41. Vasquez JK, Tal-Gan Y, Cornilescu G, Tyler KA, Blackwell HE. Simplified AIP-II peptidomimetics are potent inhibitors of *Staphylococcus aureus* AgrC quorum sensing receptors. Chembiochem. 2017;18:413-23.
<https://doi.org/10.1002/cbic.201600516>
 42. Abbas HA, Elsherbini AM, Shaldam MA. Repurposing metformin as a quorum sensing inhibitor in *Pseudomonas aeruginosa*. Afr Health Sci. 2017;17:808-19.
<https://doi.org/10.4314/ahs.v17i3.24>
 43. Chatterjee M, D'Morris S, Paul V, et al. Mechanistic understanding of phenyllactic acid mediated inhibition of quorum sensing and biofilm development in *Pseudomonas aeruginosa*. Appl Microbiol Biotechnol. 2017;101:8223-6.
<https://doi.org/10.1007/s00253-017-8546-4>
 44. Gökalsın B, Aksoydan B, Erman B, Sesal NC. Reducing virulence and biofilm of *Pseudomonas aeruginosa* by potential quorum sensing inhibitor carotenoid: zeaxanthin. Microb Ecol. 2017;74:466-73.
<https://doi.org/10.1007/s00248-017-0949-3>
 45. Capilato JN, Philippi SV, Reardon T, et al. Development of a novel series of non-natural triaryl agonists and antagonists of the *Pseudomonas aeruginosa* LasR quorum sensing receptor. Bioorg Med Chem. 2017;25:153-65.
<https://doi.org/10.1016/j.bmc.2016.10.021>
 46. Heidari A, Noshiranzadeh N, Haghi F, Bikas R. Inhibition of quorum sensing related virulence factors of *Pseudomonas aeruginosa* by pyridoxal lactohydrazone. Microb Pathog. 2017;112:103-10.
<https://doi.org/10.1016/j.micpath.2017.09.043>
 47. Kalaierasan E, Thirumalaswamy K, Harish BN, Gnanasambandam V, Sali VK, John J. Inhibition of quorum sensing-controlled biofilm formation in

- Pseudomonas aeruginosa* by quorum-sensing inhibitors. Microb Pathog. 2017;111:99-107. <https://doi.org/10.1016/j.micpath.2017.08.017>
48. Paczkowski JE, Mukherjee S, McCready AR, et al. Flavonoids suppress *Pseudomonas aeruginosa* virulence through allosteric inhibition of quorum-sensing receptors. J Biol Chem. 2017;292:4064-76. <https://doi.org/10.1074/jbc.M116.770552>
 49. Rajamanikandan S, Jeyakanthan J, Srinivasan P. Discovery of potent inhibitors targeting *Vibrio harveyi* LuxR through shape and e-pharmacophore based virtual screening and its biological evaluation. Microb Pathog. 2017;103:40-56. <https://doi.org/10.1016/j.micpath.2016.12.003>
 50. Da F, Yao L, Su Z, et al. Antisense locked nucleic acids targeting *agrA* inhibit quorum sensing and pathogenesis of community-associated methicillin-resistant *Staphylococcus aureus*. J Appl Microbiol. 2017;122:257-67. <https://doi.org/10.1111/jam.13321>
 51. Zuberi A, Misba L, Khan AU. CRISPR interference (CRISPRi) inhibition of *luxS* gene expression in *E. coli*: an approach to inhibit biofilm. Front Cell Infect Microbiol. 2017;7:214. <https://doi.org/10.3389/fcimb.2017.00214>
 52. Kang S, Kim J, Hur JK, Lee SS. CRISPR-based genome editing of clinically important *Escherichia coli* SE15 isolated from indwelling urinary catheters of patients. J Med Microbiol. 2017;66:18-25. <https://doi.org/10.1099/jmm.0.000406>
 53. Greenberg M, Kuo D, Jankowsky E, et al. Small-molecule AgrA inhibitors F12 and F19 act as antivirulence agents against Gram-positive pathogens. Sci Rep. 2018;8:14578. <https://doi.org/10.1038/s41598-018-32829-w>
 54. Kim B, Park JS, Choi HY, Yoon SS, Kim WG. Terrein is an inhibitor of quorum sensing and c-di-GMP in *Pseudomonas aeruginosa*: a connection between quorum sensing and c-di-GMP. Sci Rep. 2018;8:8617. <https://doi.org/10.1038/s41598-018-26974-5>
 55. Kalia M, Yadav VK, Singh PK, Sharma D, Narvi SS, Agarwal V. Exploring the impact of parthenolide as anti-quorum sensing and anti-biofilm agent against *Pseudomonas aeruginosa*. Life Sci. 2018;199:96-103. <https://doi.org/10.1016/j.lfs.2018.03.013>
 56. Soukarieh F, Vico Oton E, Dubern JF, et al. In silico and in vitro-guided identification of inhibitors of alkylquinolone-dependent quorum sensing in *Pseudomonas aeruginosa*. Molecules. 2018;23:257. <https://doi.org/10.3390/molecules23020257>
 57. Hansen AM, Peng P, Baldry M, et al. Lactam hybrid analogues of solonomide B and autoinducing peptides as potent *S. aureus* AgrC antagonists. Eur J Med Chem. 2018;152:370-6. <https://doi.org/10.1016/j.ejmech.2018.04.053>
 58. Karathanasi G, Bojer MS, Baldry M, et al. Linear peptidomimetics as potent antagonists of *Staphylococcus aureus* agr quorum sensing. Sci Rep. 2018;8:3562. <https://doi.org/10.1038/s41598-018-21951-4>
 59. Zhang Y, Sass A, Van Acker H, et al. Coumarin reduces virulence and biofilm formation in *Pseudomonas aeruginosa* by affecting quorum sensing, type III secretion and c-di-GMP levels. Front Microbiol. 2018 Aug 21;9:1952. <https://doi.org/10.3389/fmicb.2018.01952>
 60. Moshiri J, Kaur D, Hambira CM, et al. Identification of a small molecule anti-biofilm agent against *Salmonella enterica*. Front Microbiol. 2018;9:2804. <https://doi.org/10.3389/fmicb.2018.02804>
 61. Huggins WM, Vu Nguyen T, Hahn NA, et al. 2-Aminobenzimidazoles as antibiofilm agents against *Salmonella enterica* serovar Typhimurium. Medchemcomm. 2018;9:1547-52. <https://doi.org/10.1039/C8MD00298C>
 62. Tan J, Patil PC, Luzzio FA, Demuth DR. In vitro and in vivo activity of peptidomimetic compounds that target the periodontal pathogen *Porphyromonas gingivalis*. Antimicrob Agents Chemother. 2018;62:e00400-18. <https://doi.org/10.1128/AAC.00400-18>
 63. Xuewen H, Ping O, Zhongwei Y, et al. Eriodictyol protects against *Staphylococcus aureus*-induced lung cell injury by inhibiting alpha-hemolysin expression. World J Microbiol Biotechnol. 2018;34:64. <https://doi.org/10.1007/s11274-018-2446-3>
 64. Ping O, Ruixue Y, Jiaqiang D, et al. Subinhibitory concentrations of prim- α -glucosylcimifugin decrease the expression of alpha-hemolysin in *Staphylococcus aureus* (USA300). Evid Based Complement Alternat Med. 2018;2018:7579808. <https://doi.org/10.1155/2018/7579808>
 65. Thanissery R, Zeng D, Doyle RG, Theriot CM. A small molecule-screening pipeline to evaluate the therapeutic potential of 2-aminoimidazole molecules against *Clostridium difficile*. Front Microbiol. 2018;9:1206. <https://doi.org/10.3389/fmicb.2018.01206>
 66. Krueger E, Hayes S, Chang EH, Yutuc S, Brown AC. Receptor-based peptides for inhibition of leukotoxin activity. ACS Infect Dis. 2018;4:1073-81. <https://doi.org/10.1021/acsinfecdis.7b00230>
 67. Duan J, Li M, Hao Z, et al. Subinhibitory concentrations of resveratrol reduce alpha-hemolysin production in *Staphylococcus aureus* isolates by downregulating *saeRS*. Emerg Microbes Infect. 2018;7:136. <https://doi.org/10.1038/s41426-018-0142-x>
 68. Tang F, Li L, Meng XM, et al. Inhibition of alpha-hemolysin expression by resveratrol attenuates *Staphylococcus aureus* virulence. Microb Pathog. 2019;127:85-90. <https://doi.org/10.1016/j.micpath.2018.11.027>
 69. Chang EH, Huang J, Lin Z, Brown AC. Catechin-mediated restructuring of a bacterial toxin inhibits activity. Biochim Biophys Acta Gen Subj. 2019;1863:191-8. <https://doi.org/10.1016/j.bbagen.2018.10.011>
 70. Cascioferro S, Parrino B, Petri GL, et al. 2, 6-Disubstituted imidazo [2, 1-b][1, 3, 4] thiazole derivatives as potent staphylococcal biofilm inhibitors. Eur J Med Chem. 2019;167:200-10. <https://doi.org/10.1016/j.ejmech.2019.02.007>
 71. Yuan Y, Zai Y, Xi X, et al. A novel membrane-disruptive antimicrobial peptide from frog skin secretion against

- cystic fibrosis isolates and evaluation of anti-MRSA effect using *Galleria mellonella* model. *Biochim Biophys Acta Gen Subj.* 2019;1863:849-56. <https://doi.org/10.1016/j.bbagen.2019.02.013>
72. Kang J, Dietz MJ, Li B. Antimicrobial peptide LL-37 is bactericidal against *Staphylococcus aureus* biofilms. *PLoS One.* 2019;14:e0216676. <https://doi.org/10.1371/journal.pone.0216676>
 73. Yuan Y, Qu K, Tan D, et al. Isolation and characterization of a bacteriophage and its potential to disrupt multi-drug resistant *Pseudomonas aeruginosa* biofilms. *Microb Pathog.* 2019;128:329-36. <https://doi.org/10.1016/j.micpath.2019.01.032>
 74. Liu Y, Mi Z, Mi L, et al. Identification and characterization of capsule depolymerase Dpo48 from *Acinetobacter baumannii* phage IME200. *PeerJ.* 2019;7:e6173. <https://doi.org/10.7717/peerj.6173>
 75. Qayyum S, Sharma D, Bisht D, Khan AU. Identification of factors involved in *Enterococcus faecalis* biofilm under quercetin stress. *Microb Pathog.* 2019;126:205-11. <https://doi.org/10.1016/j.micpath.2018.11.013>
 76. Kalia VC, Patel SKS, Kang YC, Lee JK. Quorum sensing inhibitors as antipathogens: biotechnological applications. *Biotechnol Adv.* 2019;37:68-90. <https://doi.org/10.1016/j.biotechadv.2018.11.006>
 77. Namivandi-Zangeneh R, Yang Y, Xu S, Wong EH, Boyer C. Antibiofilm platform based on the combination of antimicrobial polymers and essential oils. *Biomacromolecules.* 2020;21:262-72. <https://doi.org/10.1021/acs.biomac.9b01278>
 78. Abutaleb NS, Seleem MN. Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies. *Int J Antimicrob Agents.* 2020;55:105828. <https://doi.org/10.1016/j.ijantimicag.2019.10.009>
 79. Valliammai A, Selvaraj A, Yuvashree U, Aravindraja C, Karutha Pandian S. *sarA*-dependent antibiofilm activity of thymol enhances the antibacterial efficacy of rifampicin against *Staphylococcus aureus*. *Front Microbiol.* 2020;11:1744. <https://doi.org/10.3389/fmicb.2020.01744>
 80. Zhong L, Ravichandran V, Zhang N, et al. Attenuation of *Pseudomonas aeruginosa* quorum sensing by natural products: virtual screening, evaluation and biomolecular interactions. *Int J Mol Sci.* 2020;21:2190. <https://doi.org/10.3390/ijms21062190>
 81. D'Andrea MM, Frezza D, Romano E, et al. The lytic bacteriophage vB_EfaH_EF1TV, a new member of the *Herelleviridae* family, disrupts biofilm produced by *Enterococcus faecalis* clinical strains. *J Glob Antimicrob Resist.* 2020;21:68-75. <https://doi.org/10.1016/j.jgar.2019.10.019>
 82. Pellissery AJ, Vinayamohan PG, Venkitanarayanan K. In vitro antivirulence activity of baicalin against *Clostridioides difficile*. *J Med Microbiol.* 2020;69:631-9. <https://doi.org/10.1099/jmm.0.001179>
 83. Cascioferro S, Parrino B, Carbone D, et al. Thiazoles, their benzofused systems, and thiazolidinone derivatives: versatile and promising tools to combat antibiotic resistance. *J Med Chem.* 2020;63:7923-56. <https://doi.org/10.1021/acs.jmedchem.9b01245>
 84. Carbone A, Cascioferro S, Parrino B, et al. Thiazole analogues of the marine alkaloid nortopsentin as inhibitors of bacterial biofilm formation. *Molecules.* 2020;26:81. <https://doi.org/10.3390/molecules26010081>
 85. Weng Y, Bina TF, Bina XR, Bina JE. ToxR mediates the antivirulence activity of phenyl-arginine- β -naphthylamide to attenuate *Vibrio cholerae* virulence. *Infect Immun.* 2021;89:e0014721. <https://doi.org/10.1128/IAI.00147-21>
 86. Cortes-López H, Castro-Rosas J, García-Contreras R, et al. Antivirulence activity of a dietary phytochemical: hibiscus acid isolated from *Hibiscus sabdariffa* L. reduces the virulence of *Pseudomonas aeruginosa* in a mouse infection model. *J Med Food.* 2021;24:934-43. <https://doi.org/10.1089/jmf.2020.0135>
 87. Parrino B, Carbone D, Cascioferro S, et al. 1,2,4-Oxadiazole topsentin analogs as staphylococcal biofilm inhibitors targeting the bacterial transpeptidase sortase A. *Eur J Med Chem.* 2021;209:112892. <https://doi.org/10.1016/j.ejmech.2020.112892>
 88. Anju VT, Busi S, Ranganathan S, et al. Sesamin and sesamol rescues *Caenorhabditis elegans* from *Pseudomonas aeruginosa* infection through the attenuation of quorum sensing regulated virulence factors. *Microb Pathog.* 2021;155:104912. <https://doi.org/10.1016/j.micpath.2021.104912>
 89. Chang EH, Brown AC. Epigallocatechin gallate alters leukotoxin secretion and *Aggregatibacter actinomycetemcomitans* virulence. *J Pharm Pharmacol.* 2021;73:505-14. <https://doi.org/10.1093/jpp/rgaa051>
 90. Bernabè G, Dal Pra M, Ronca V, et al. A novel azadervative inhibits agr quorum sensing signaling and synergizes methicillin-resistant *Staphylococcus aureus* to clindamycin. *Front Microbiol.* 2021;12:610859. <https://doi.org/10.3389/fmicb.2021.610859>
 91. Mahdally NH, George RF, Kashef MT, Al-Ghobashy M, Murad FE, Attia AS. Staquorsin: a novel *Staphylococcus aureus* agr-mediated quorum sensing inhibitor impairing virulence in vivo without notable resistance development. *Front Microbiol.* 2021;12:700494. <https://doi.org/10.3389/fmicb.2021.700494>

Please cite this article as:

Dehbanipour R, Ghalavand Z. Anti-virulence therapeutic strategies against bacterial infections: recent advances. *GERMS.* 2022;12(2):262-275. doi: 10.18683/germs.2022.1328

Table 1. Inhibitors of bacterial adherence, biofilm formation, quorum sensing systems, toxin production and function, and two component systems

Substance	Inhibitory activity	Targets	Virulence factors affected	First author, year
MEDI4893 (mAb)	Anti-toxin	<i>S. aureus</i>	• Inhibition of oligomerization and pore formation by α -hemolysin	Yu et al., 2017 ¹⁷
Sclareol	Anti-toxin Anti-QS	<i>S. aureus</i>	• Reduced α -hemolysin production • Downregulation of <i>hla</i> and <i>RNAIII</i> expression • Reduced hemolysis	Ouyang et al., 2017 ³³
Dracorhodin perchlorate	Anti-toxin Anti-QS	<i>S. aureus</i>	• Reduced α -hemolysin production • Downregulation of <i>hla</i> and <i>RNAIII</i> expression • Reduced hemolysis	Liu et al., 2017 ³⁴
Chalcone	Anti-toxin Anti-SrtA Anti-QS Anti-biofilm	<i>S. aureus</i>	• Downregulation of <i>hla</i> and <i>agrA</i> expression • Reduced α -hemolysin production • Inhibition of SrtA activity • Reduced adherence to fibronectin • Reduced hemolysis • Reduced biofilm formation	Zhang et al., 2017 ³⁵
Lysionotin	Anti-toxin Anti-QS	<i>S. aureus</i>	• Downregulation of <i>hla</i> , and <i>agr</i> expression • Reduced α -hemolysin production	Teng et al., 2017 ³⁶
5-benzylidene-4-oxazolidinones	Anti-biofilm	<i>S. aureus</i>	• Reduced biofilm production • Biofilm dispersion	Edwards et al., 2017 ³⁷
Kaempferol	Anti-SrtA Anti-biofilm	<i>S. aureus</i>	• Reduced biofilm production (inhibition of initial attachment) • Inhibition of SrtA activity • Downregulation of <i>clfA</i> , <i>clfB</i> , <i>fnbA</i> and <i>fnbB</i> expression	Ming et al., 2017 ³⁸
3F1 compound	Anti-biofilm	<i>Streptococcus mutans</i>	• Biofilm dispersion	Garcia et al., 2017 ³⁹
Bicyclo [2.2.1] hept-5-ene-2,3-dicarboxylic acid	Anti-QS Anti-biofilm	<i>Vibrio harveyi</i>	• Reduced biofilm production • Disintegrated mature biofilm • Reduced swarming and swimming	Rajamanikandan et al., 2017 ⁴⁰
2,6-dimethylpyridine 1-oxide				
AIP-II peptidomimetics	Anti-QS	<i>S. aureus</i>	• Inhibition of Agr-system activity and quorum sensing	Vasquez et al., 2017 ⁴¹

Substance	Inhibitory activity	Targets	Virulence factors affected	First author, year
Metformin	Anti-QS Anti-biofilm Anti-toxin	<i>P. aeruginosa</i> PAO1	<ul style="list-style-type: none"> • Reduced biofilm, pyocyanin, proteases, hemolysin and elastase production • Reduced swimming and twitching motility 	Abbas et al., 2017 ⁴²
Phenyllactic acid	Anti-QS Anti-biofilm Anti-toxin	<i>P. aeruginosa</i> PAO1 and clinical isolates	<ul style="list-style-type: none"> • Reduced pyocyanin, proteases, rhamnolipid, and hemolysin production • Reduced swarming motility • Reduced biofilm production 	Chatterjee et al., 2017 ⁴³
Zeaxanthin	Anti-QS Anti-biofilm	<i>P. aeruginosa</i> PAO1	<ul style="list-style-type: none"> • Reduced biofilm formation • Downregulated <i>rhlA</i> and <i>lasB</i> expression 	Gökalsın et al., 2017 ⁴⁴
Triaryl derivatives	Anti-QS	<i>P. aeruginosa</i>	<ul style="list-style-type: none"> • Inhibition of quorum-sensing receptor LasR 	Capilato et al., 2017 ⁴⁵
Pyridoxal lactohydrazone	Anti-QS Anti-biofilm	<i>P. aeruginosa</i> PAO1	<ul style="list-style-type: none"> • Reduced biofilm, alginate and pyocyanin production • Reduced swarming and twitching motility 	Heidari et al., 2017 ⁴⁶
N-(4-{fluoroanilno}-butanoyl)-L-homoserine lactone N-(4-{chloroanilno}-butanoyl)-L-homoserine lactone	Anti-QS Anti-biofilm	<i>P. aeruginosa</i> PA330 <i>P. aeruginosa</i> PA282	<ul style="list-style-type: none"> • Reduced biofilm production 	Kalaierasan et al., 2017 ⁴⁷
Flavonoids	Anti-QS	<i>P. aeruginosa</i> PA14	<ul style="list-style-type: none"> • Reduced pyocyanin production and swarming motility • <i>rhlA</i> transcription inhibition 	Paczkowski et al., 2017 ⁴⁸
3-(2,4-dichlorophenyl)-1-(1Hpyrrol-2-yl)-2-propen-1-one	Anti-QS Anti-biofilm	<i>V. harveyi</i>	<ul style="list-style-type: none"> • Reduced biofilm production • Biofilm disintegration • Swimming and swarming motility reduction 	Rajamanikandan et al., 2017 ⁴⁹
(KFF)3 K peptide-conjugated locked nucleic acids	Anti-QS Anti-toxin	<i>S. aureus</i>	<ul style="list-style-type: none"> • Reduced expression of <i>RNAIII</i>, <i>psmA</i>, <i>psmβ</i>, <i>hla</i>, and <i>pvl</i> 	Da et al., 2017 ⁵⁰
CRISPR interference	Anti-QS Anti-biofilm	<i>E. coli</i> AK-117	<ul style="list-style-type: none"> • Reduced biofilm formation 	Zuberi et al., 2017 ⁵¹
CRISPR-Cas9	Anti-QS Anti-biofilm	<i>E. coli</i> SE15	<ul style="list-style-type: none"> • Reduced biofilm formation • Downregulation of <i>mqsR</i>, <i>pgaB</i>, <i>pgaC</i>, <i>csgE</i>, and <i>csgF</i> 	Kang et al., 2017 ⁵²
AR-301 (mAb)	Anti-toxin	<i>S. aureus</i>	<ul style="list-style-type: none"> • Neutralization of α-hemolysin 	Francois et al., 2018 ¹⁸
Biaryl hydroxyketones	Anti-QS Anti-toxin	<i>S. aureus</i>	<ul style="list-style-type: none"> • Reduced <i>RNAIII</i>, <i>psmA</i> and <i>hla</i> transcription 	Greenberg et al., 2018 ⁵³

Substance	Inhibitory activity	Targets	Virulence factors affected	First author, year
Savirin	Anti-TCS	<i>S. aureus</i>	<ul style="list-style-type: none"> • Downregulation of AgrCA-regulated genes expression • Inhibition of RNAPIII production 	Salam et al., 2018 ²⁷
Terrein	Anti-QS Anti-biofilm	<i>P. aeruginosa</i> PAO1	<ul style="list-style-type: none"> • Reduced elastase, pyocyanin, rhamnolipid, and biofilm production • Attenuated in vivo virulence of <i>P. aeruginosa</i> PAO1 toward <i>C. elegans</i> and mice 	Kim et al., 2018 ⁵⁴
Parthenolide	Anti-QS Anti-biofilm	<i>P. aeruginosa</i> PAO1	<ul style="list-style-type: none"> • Reduced pyocyanin, proteases, and biofilm production • Reduced swarming motility 	Kalia et al., 2018 ⁵⁵
4-amino-quinolone-based compounds	Anti-QS Anti-biofilm	<i>P. aeruginosa</i> PAO1-L <i>P. aeruginosa</i> PA14	<ul style="list-style-type: none"> • Reduced biofilm and pyocyanin production 	Soukarieh et al., 2018 ⁵⁶
Lactam hybrids of solonamide B and AIP	Anti-QS	<i>S. aureus</i> RN10829 reporter strain	<ul style="list-style-type: none"> • Inhibition of AgrC 	Hansen et al., 2018 ⁵⁷
Linear peptidomimetics	Anti-QS Anti-toxin	<i>S. aureus</i> 8325-4 <i>S. aureus</i> reporter strains	<ul style="list-style-type: none"> • Reduced expression of RNAPIII • Reduced <i>hla</i> expression 	Karathanasi et al., 2018 ⁵⁸
Coumarin	Anti-QS Anti-biofilm	<i>P. aeruginosa</i> PAO1 and clinical isolates	<ul style="list-style-type: none"> • Reduced biofilm production • Down-regulation of <i>lasI</i>, <i>rhlI</i>, <i>rhlR</i>, <i>pqsB</i>, <i>pqsC</i>, <i>pqsH</i>, <i>ambBCDE</i> • Reduced protease and pyocyanin production • Reduced expression of T3SS secretion system-associated genes 	Zhang et al., 2018 ⁵⁹
T315 compound	Anti-biofilm	<i>S. enterica</i> serovar Typhimurium, <i>S. enterica</i> serovar Typhi, <i>A. baumannii</i>	<ul style="list-style-type: none"> • Reduced biofilm production 	Moshiri et al., 2018 ⁶⁰
2-aminobenzimidazole derivatives	Anti-biofilm	<i>S. enterica</i> serovar Typhimurium	<ul style="list-style-type: none"> • Reduced biofilm production 	Huggins et al., 2018 ⁶¹
Peptidomimetic compounds	Anti-biofilm	<i>Porphyromonas gingivalis</i>	<ul style="list-style-type: none"> • Three-species biofilm inhibition 	Tan et al., 2018 ⁶²
Eriodictyol	Anti-toxin Anti-QS	<i>S. aureus</i>	<ul style="list-style-type: none"> • Downregulation of <i>hla</i> and RNAPIII expression • Reduced α-hemolysin production • Reduced hemolysis 	Xu et al., 2018 ⁶³

Substance	Inhibitory activity	Targets	Virulence factors affected	First author, year
Prim-O-Glucosylcimifugin	Anti-toxin Anti-QS	<i>S. aureus</i>	<ul style="list-style-type: none"> • Reduced α-hemolysin production • Downregulation of <i>hla</i> and <i>RNAIII</i> expression • Reduced hemolysis 	Ping et al., 2018 ⁶⁴
2-aminoimidazole derivatives	Anti-toxin	<i>C. difficile</i>	<ul style="list-style-type: none"> • Reduced toxin activity 	Thanissery et al., 2018 ⁶⁵
Peptides	Anti-toxin	<i>A. actinomycetemcomitans</i>	<ul style="list-style-type: none"> • Inhibition of LtxA-mediated cytotoxicity 	Krueger et al., 2018 ⁶⁶
Resveratrol	Anti-toxin Anti-QS	<i>S. aureus</i>	<ul style="list-style-type: none"> • Downregulation of <i>hla</i>, <i>RNAIII</i> and <i>saeRS</i> expression • Reduced α-hemolysin production 	Duan et al., 2018 ⁶⁷ Tang et al., 2019 ⁶⁸
Galloylated catechins	Anti-toxin	<i>A. actinomycetemcomitans</i>	<ul style="list-style-type: none"> • Inhibition of LtxA-mediated cytotoxicity 	Chang et al., 2019 ⁶⁹
2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazole derivatives	Anti-SrtA Anti-biofilm	<i>Staphylococcus</i>	<ul style="list-style-type: none"> • Inhibition of SrtA • Inhibition of biofilm formation 	Cascioferro et al., 2019 ⁷⁰
HC104A and HC106A	Anti-TCS	<i>M. tuberculosis</i>	<ul style="list-style-type: none"> • Downregulation of the DosR regulon genes and disruption of signal transduction 	Zheng et al., 2019 ²⁶
Japonicin-2LF	Anti-biofilm	<i>S. aureus</i> , methicillin-resistant <i>S. aureus</i> , <i>E. coli</i>	<ul style="list-style-type: none"> • Inhibition and eradication of biofilms 	Yuan et al., 2019 ⁷¹
LL-37	Anti-biofilm	<i>S. aureus</i>	<ul style="list-style-type: none"> • Eradication of biofilms 	Kang et al., 2019 ⁷²
vB_PaeM_LS1	Anti-biofilm	<i>P. aeruginosa</i>	<ul style="list-style-type: none"> • Inhibition and eradication of biofilms 	Yuan et al., 2019 ⁷³
Dpo48	Anti-biofilm	<i>A. baumannii</i>	<ul style="list-style-type: none"> • Eradication of biofilms 	Liu et al., 2019 ⁷⁴
Flavonoids (e.g., quercetin)	Anti-biofilm	<i>Enterococcus faecalis</i>	<ul style="list-style-type: none"> • Inhibition of biofilm formation 	Qayyum et al., 2019 ⁷⁵
Paraoxonases (e.g., acylase I)	Anti-QS	<i>Aeromonas hydrophila</i> , <i>Pseudomonas putida</i> , <i>P. aeruginosa</i>	<ul style="list-style-type: none"> • Inhibition of AHL-mediated biofilm formation 	Kalia et al., 2019 ⁷⁶
Carvacrol + eugenol	Anti-biofilm	<i>P. aeruginosa</i>	<ul style="list-style-type: none"> • Inhibition of biofilm formation 	Namivandi-Zangeneh et al., 2020 ⁷⁷
Auranofin	Anti-adhesion	Vancomycin-resistant enterococci (VRE)	<ul style="list-style-type: none"> • Adherence-inhibition activity by protease and lipase inhibitions 	Abutaleb et al., 2020 ⁷⁸
Clove	Anti-QS Anti-biofilm	<i>E. coli</i> , <i>P. aeruginosa</i> , <i>K. pneumoniae</i> , <i>A. baumannii</i> , <i>S. aureus</i>	<ul style="list-style-type: none"> • Disruption of QS communication • Inhibition of AHL synthesis 	Alibi et al., 2020 ²³

Substance	Inhibitory activity	Targets	Virulence factors affected	First author, year
Thyme (thymol)	Anti-biofilm	<i>E. coli</i> , <i>P. aeruginosa</i> , <i>K. pneumoniae</i> , <i>A. baumannii</i> , <i>S. aureus</i>	<ul style="list-style-type: none"> • Downregulation of <i>sarA</i> gene • Eradication of biofilms 	Alibi et al., 2020 ²³ , Valliammai et al., 2020 ⁷⁹
Catechin-7-xyloside/ sappanol/ butein (plant-based natural products)	Anti-biofilm Anti-QS	<i>P. aeruginosa</i>	<ul style="list-style-type: none"> • Suppression of quorum sensing by interaction with LasR 	Zhong et al., 2020 ⁸⁰
INP0341 (a salicylidene acylhydrazide)	Anti-toxin	<i>P. aeruginosa</i>	<ul style="list-style-type: none"> • Prevention of toxin delivery 	Sharma et al., 2020 ¹³
vB_EfaH_EF1TV	Anti-biofilm	<i>E. faecalis</i>	<ul style="list-style-type: none"> • Biofilm eradication 	D'Andrea et al., 2020 ⁸¹
Baicalin	Anti-toxin	<i>C. difficile</i>	<ul style="list-style-type: none"> • Reduction of toxin synthesis 	Pellissery et al., 2020 ⁸²
Thiazole derivatives	Anti-biofilm	Gram positive-Gram negative pathogens	<ul style="list-style-type: none"> • Inhibition of biofilm formation 	Cascioferro et al., 2020 ⁸³ , Carbone et al., 2021 ⁸⁴
Phenyl-arginine- naphthylamide (PAbN)	Anti-toxin	<i>Vibrio cholerae</i>	<ul style="list-style-type: none"> • Reduce cholera toxin (CT) and the toxin-coregulated pilus (TCP) production by activating a ToxR-dependent metabolic feedback mechanism 	Weng et al., 2021 ⁸⁵
Hibiscus acid	Anti-QS Anti-biofilm	<i>P. aeruginosa</i>	<ul style="list-style-type: none"> • Inhibition of violacein production • Reduction of biofilm formation 	Cortes-López et al., 2021 ⁸⁶
1,2,4-Oxadiazole topsentin analogs	Anti-SrtA Anti-biofilm	<i>S. aureus</i>	<ul style="list-style-type: none"> • Inhibition of SrtA • Inhibition of biofilm formation 	Parrino et al., 2021 ⁸⁷
DEXT-3 + C-30	Anti-biofilm Anti-toxin Anti-QS	<i>P. aeruginosa</i>	<ul style="list-style-type: none"> • Inhibition of biofilm production • Inhibition of type III secretion • Inhibition of LasR QS-system 	Aburto-Rodríguez et al., 2021 ³⁰
Lignans (sesamin and sesamol)	Anti-biofilm Anti-QS	<i>P. aeruginosa</i>	<ul style="list-style-type: none"> • Inhibition of biofilm formation • Attenuation of QS pathways 	Anju et al., 2021 ⁸⁸
Epigallocatechin gallate	Anti-toxin	<i>A. actinomycetemcomitans</i>	<ul style="list-style-type: none"> • Inhibition of toxin secretion 	Wu et al., 2021 ¹⁶ , Chang et al., 2021 ⁸⁹
Azan-7	Anti-QS	MRSA	<ul style="list-style-type: none"> • Inhibition of agr quorum sensing signaling 	Bernabe et al., 2021 ⁹⁰
Staquorsin	Anti-QS	<i>S. aureus</i>	<ul style="list-style-type: none"> • Inhibition of Agr-system activity and quorum sensing • Downregulation of the alpha and delta-hemolytic activities, lipolytic activity • Downregulation of the RNA III transcript 	Mahdally et al., 2021 ⁹¹